Myles Minter

Alec Stranahan

Ananda Ghosh

Carter L. Gould

Jeffrey Hung

Pete Stavropoulos

Thomas Shrader

Yaron Werber

Corinne Jenkins

Douglas Macpherson

Emily

Graig Suvannavejh

Julian Pino

Michael Riad

Samantha Schaeffer

Sarah Schram

Steven Ayanov

Tom Shrader

- Alector expects **top-line Phase 3 data for latazimumab** in Frontotemporal Dementia (FTD GRN) by **mid-Q4 2025**.  **[1653087_2152870_1]**  This drug has received breakthrough therapy, fast track, and orphan drug designation.  **[1653087_2152870_1]** 
- The company's partnership with GSK for its progranulin elevating franchise includes **$700 million in upfront payments** and up to **$1.5 billion in potential development and commercial milestones**.  **[1653087_2152870_4]** 
- Nivisibart, developed in collaboration with GSK for Alzheimer's disease, has **completed enrollment in its Phase 2 trial**, with an **independent interim analysis expected in 2026**.  **[1653087_2152870_1]** **[1653087_2152870_4]** 
- Alector is advancing its proprietary Elektor Brain Carrier (ABC) technology, targeting **first-in-human trials in 2026** for its ABC-enabled anti-amyloid beta antibodies (AL037 and AL137) for Alzheimer's disease, and **2027** for its ABC-enabled GK's enzyme replacement therapy (AL050) for Parkinson's disease.  **[1653087_2152870_1]** **[1653087_2152870_7]** **[1653087_2152870_13]**

Alector Provides Update on Progranulin Franchise and Brain Carrier Programs

Alector (ALEC)